Asthma Clinical Trial
— NAVIGATOROfficial title:
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)
Verified date | October 2021 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma
Status | Completed |
Enrollment | 1061 |
Est. completion date | November 12, 2020 |
Est. primary completion date | September 8, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 80 Years |
Eligibility | Inclusion Criteria: - Age. 12-80 - Documented physician-diagnosed asthma for at least 12 months - Subjects who have received a physician-prescribed asthma controller medication with medium or high dose ICS for at least 12 months. - Documented treatment with a total daily dose of either medium or high dose ICS (= 500 µg fluticasone propionate dry powder formulation equivalent total daily dose) for at least 3 months. - At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months. - Morning pre-BD FEV1 <80% predicted normal (<90% for subjects 12-17 yrs) - Evidence of asthma as documented by either: Documented historical reversibility of FEV1 =12% and =200 mL in the previous 12 months OR Post-BD (albuterol/salbutamol) reversibility of FEV1 =12% and =200 mL during screening. - Documented history of at least 2 asthma exacerbation events within 12 months. - ACQ-6 score =1.5 at screening and on day of randomization Exclusion Criteria: - Pulmonary disease other than asthma. - History of cancer. - History of a clinically significant infection. - Current smokers or subjects with smoking history =10 pack-years and subjects using vaping products, including electronic cigarettes. - History of chronic alcohol or drug abuse within 12 months. - Hepatitis B, C or HIV. - Pregnant or breastfeeding. - History of anaphylaxis following any biologic therapy. - Subject randomized in the current study or previous tezepelumab studies. |
Country | Name | City | State |
---|---|---|---|
Argentina | Research Site | Buenos Aires | |
Argentina | Research Site | Caba | |
Argentina | Research Site | Caba | |
Argentina | Research Site | Ciudad de Buenos Aires | |
Argentina | Research Site | Córdoba | |
Argentina | Research Site | Mendoza | |
Argentina | Research Site | Nueve de julio | |
Argentina | Research Site | Quilmes | |
Australia | Research Site | Campbelltown | |
Australia | Research Site | Kent Town | |
Australia | Research Site | Melbourne | |
Australia | Research Site | Nedlands | |
Australia | Research Site | New Lambton | |
Australia | Research Site | Spearwood | |
Australia | Research Site | Westmead | |
Australia | Research Site | Woolloongabba | |
Austria | Research Site | Klagenfurt | |
Austria | Research Site | Linz | |
Austria | Research Site | Salzburg | |
Austria | Research Site | Wien | |
Austria | Research Site | Wien | |
Brazil | Research Site | Blumenau | |
Brazil | Research Site | Botucatu | |
Brazil | Research Site | Curitiba | |
Brazil | Research Site | Porto Alegre | |
Brazil | Research Site | Porto Alegre | |
Brazil | Research Site | Porto Alegre | |
Brazil | Research Site | Porto Alegre | |
Brazil | Research Site | Porto Alegre | |
Brazil | Research Site | Recife | |
Brazil | Research Site | Salvador | |
Brazil | Research Site | Santo Andre | |
Brazil | Research Site | Sao Bernardo do Campo | |
Brazil | Research Site | Sorocaba | |
Brazil | Research Site | Vitória | |
Canada | Research Site | Ajax | Ontario |
Canada | Research Site | Burlington | Ontario |
Canada | Research Site | Calgary | Alberta |
Canada | Research Site | Mississauga | Ontario |
Canada | Research Site | Montreal | Quebec |
Canada | Research Site | Ottawa | Ontario |
Canada | Research Site | Quebec | |
Canada | Research Site | Sherwood Park | Alberta |
Canada | Research Site | St Charles Borromee | Quebec |
Canada | Research Site | Trois-Rivières | Quebec |
Canada | Research Site | Vancouver | British Columbia |
Canada | Research Site | Windsor | Ontario |
France | Research Site | Brest Cedex | |
France | Research Site | GRENOBLE Cedex 9 | |
France | Research Site | Le Kremlin Bicêtre | |
France | Research Site | Lille Cedex | |
France | Research Site | Lyon Cedex 04 | |
France | Research Site | MARSEILLE Cedex 20 | |
France | Research Site | Montpellier Cedex 5 | |
France | Research Site | Nantes Cedex 1 | |
France | Research Site | Paris | |
France | Research Site | PARIS Cedex 12 | |
France | Research Site | Paris Cedex 18 | |
France | Research Site | Pessac | |
France | Research Site | Strasbourg Cedex | |
France | Research Site | Toulouse CEDEX 09 | |
Germany | Research Site | Bamberg | |
Germany | Research Site | Berlin | |
Germany | Research Site | Berlin | |
Germany | Research Site | Frankfurt | |
Germany | Research Site | Frankfurt am Main | |
Germany | Research Site | Hamburg | |
Germany | Research Site | Hamburg | |
Germany | Research Site | Hannover | |
Germany | Research Site | Hannover | |
Germany | Research Site | Landsberg | |
Germany | Research Site | Leipzig | |
Germany | Research Site | Leipzig | |
Germany | Research Site | Lübeck | |
Germany | Research Site | Mainz | |
Israel | Research Site | Ashkelon | |
Israel | Research Site | Haifa | |
Israel | Research Site | Jerusalem | |
Israel | Research Site | Jerusalem | |
Israel | Research Site | Kfar Saba | |
Israel | Research Site | Rehovot | |
Japan | Research Site | Bunkyo-ku | |
Japan | Research Site | Chuo-ku | |
Japan | Research Site | Chuo-ku | |
Japan | Research Site | Chuo-ku | |
Japan | Research Site | Edogawa-ku | |
Japan | Research Site | Fujieda-shi | |
Japan | Research Site | Fukuoka-shi | |
Japan | Research Site | Fukuoka-shi | |
Japan | Research Site | Fukuoka-shi | |
Japan | Research Site | Habikino-shi | |
Japan | Research Site | Hamamatsu-shi | |
Japan | Research Site | Higashiibaraki-gun | |
Japan | Research Site | Himeji-shi | |
Japan | Research Site | Hitachi-shi | |
Japan | Research Site | Itabashi-ku | |
Japan | Research Site | Itabashi-ku | |
Japan | Research Site | Kagoshima-shi | |
Japan | Research Site | Kagoshima-shi | |
Japan | Research Site | Kanazawa-shi | |
Japan | Research Site | Kanazawa-shi | |
Japan | Research Site | Kasuga-shi | |
Japan | Research Site | Kishiwada-shi | |
Japan | Research Site | Kitakyusyu | |
Japan | Research Site | Koga-shi | |
Japan | Research Site | Matsusaka-shi | |
Japan | Research Site | Meguro-ku | |
Japan | Research Site | Meguro-ku | |
Japan | Research Site | Minato-ku | |
Japan | Research Site | Minato-ku | |
Japan | Research Site | Minato-ku | |
Japan | Research Site | Mizunami-shi | |
Japan | Research Site | Nagaoka-shi | |
Japan | Research Site | Niigata-shi | |
Japan | Research Site | Ogaki-shi | |
Japan | Research Site | Ohota-ku | |
Japan | Research Site | Omuta-shi | |
Japan | Research Site | Sagamihara-shi | |
Japan | Research Site | Sapporo-shi | |
Japan | Research Site | Sapporo-shi | |
Japan | Research Site | Setagaya-ku | |
Japan | Research Site | Shibuya-ku | |
Japan | Research Site | Shinagawa-ku | |
Japan | Research Site | Shinagawa-ku | |
Japan | Research Site | Shinjuku-ku | |
Japan | Research Site | Shinjuku-ku | |
Japan | Research Site | Sumida-ku | |
Japan | Research Site | Takamatsu-shi | |
Japan | Research Site | Toshima-ku | |
Japan | Research Site | Toshima-ku | |
Japan | Research Site | Ube | |
Japan | Research Site | Yokkaichi-shi | |
Japan | Research Site | Yokohama-shi | |
Japan | Research Site | Yokohama-shi | |
Japan | Research Site | Yokohama-shi | |
Japan | Research Site | Yoshida-gun | |
Korea, Republic of | Research Site | Bucheon-si | |
Korea, Republic of | Research Site | Cheongju-si | |
Korea, Republic of | Research Site | Daegu | |
Korea, Republic of | Research Site | Daegu | |
Korea, Republic of | Research Site | Jeju-si | |
Korea, Republic of | Research Site | Jeonju-si | |
Korea, Republic of | Research Site | Seongnam-si | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Suwon-si | |
Russian Federation | Research Site | Izhevsk | |
Russian Federation | Research Site | Moscow | |
Russian Federation | Research Site | Moscow | |
Russian Federation | Research Site | St-Petersburg | |
Saudi Arabia | Research Site | Jeddah | |
Saudi Arabia | Research Site | Jeddah | |
South Africa | Research Site | Bellville | |
South Africa | Research Site | Boksburg North | |
South Africa | Research Site | Cape Town | |
South Africa | Research Site | Cape Town | |
South Africa | Research Site | Durban | |
South Africa | Research Site | Durban | |
South Africa | Research Site | Durban | |
South Africa | Research Site | Durban | |
South Africa | Research Site | Johannesburg | |
South Africa | Research Site | Johannesburg | |
South Africa | Research Site | Johannesburg | |
South Africa | Research Site | Lenasia Ext8 | |
South Africa | Research Site | Middelburg | |
South Africa | Research Site | Mowbray | |
South Africa | Research Site | Parow | |
South Africa | Research Site | Pretoria | |
South Africa | Research Site | Umkomaas | |
South Africa | Research Site | Witbank | |
Taiwan | Research Site | Hsinchu | |
Taiwan | Research Site | Kaohsiung | |
Taiwan | Research Site | Kaohsiung City | |
Taiwan | Research Site | Kaohsiung Hsien | |
Taiwan | Research Site | Taichung | |
Taiwan | Research Site | Tainan City | |
Taiwan | Research Site | Taipei | |
Taiwan | Research Site | Taipei | |
Taiwan | Research Site | Yilan | |
Ukraine | Research Site | Ivano-Frankivsk | |
Ukraine | Research Site | Kharkiv Region | |
United Kingdom | Research Site | London | |
United States | Research Site | Allen | Texas |
United States | Research Site | Amarillo | Texas |
United States | Research Site | Anderson | South Carolina |
United States | Research Site | Ann Arbor | Michigan |
United States | Research Site | Bakersfield | California |
United States | Research Site | Boerne | Texas |
United States | Research Site | Boise | Idaho |
United States | Research Site | Boston | Massachusetts |
United States | Research Site | Bronx | New York |
United States | Research Site | Bronx | New York |
United States | Research Site | Brooklyn | New York |
United States | Research Site | Celebration | Florida |
United States | Research Site | Charlotte | North Carolina |
United States | Research Site | Cincinnati | Ohio |
United States | Research Site | Cincinnati | Ohio |
United States | Research Site | Columbia | South Carolina |
United States | Research Site | Cudahy | Wisconsin |
United States | Research Site | Dallas | Texas |
United States | Research Site | Dallas | Texas |
United States | Research Site | Denver | Colorado |
United States | Research Site | Dothan | Alabama |
United States | Research Site | Edmond | Oklahoma |
United States | Research Site | Encinitas | California |
United States | Research Site | Fall River | Massachusetts |
United States | Research Site | Fayetteville | Georgia |
United States | Research Site | Flint | Michigan |
United States | Research Site | Foley | Alabama |
United States | Research Site | Fort Mitchell | Kentucky |
United States | Research Site | Gainesville | Georgia |
United States | Research Site | Gastonia | North Carolina |
United States | Research Site | Gilbert | Arizona |
United States | Research Site | Greenville | South Carolina |
United States | Research Site | Huntington Beach | California |
United States | Research Site | Kissimmee | Florida |
United States | Research Site | Kissimmee | Florida |
United States | Research Site | Lake Charles | Louisiana |
United States | Research Site | Lampasas | Texas |
United States | Research Site | Las Vegas | Nevada |
United States | Research Site | Las Vegas | Nevada |
United States | Research Site | Lincoln | Nebraska |
United States | Research Site | Long Beach | California |
United States | Research Site | Los Angeles | California |
United States | Research Site | Louisville | Kentucky |
United States | Research Site | Madison | Wisconsin |
United States | Research Site | Manassas | Virginia |
United States | Research Site | Mayfield Heights | Ohio |
United States | Research Site | McAllen | Texas |
United States | Research Site | Medford | Oregon |
United States | Research Site | Michigan City | Indiana |
United States | Research Site | Mission Viejo | California |
United States | Research Site | New Haven | Connecticut |
United States | Research Site | New York | New York |
United States | Research Site | New York | New York |
United States | Research Site | New York | New York |
United States | Research Site | New York | New York |
United States | Research Site | Newport Beach | California |
United States | Research Site | Northfield | New Jersey |
United States | Research Site | Northridge | California |
United States | Research Site | Novi | Michigan |
United States | Research Site | Oklahoma City | Oklahoma |
United States | Research Site | Orlando | Florida |
United States | Research Site | Orlando | Florida |
United States | Research Site | Palm Desert | California |
United States | Research Site | Panama City | Florida |
United States | Research Site | Pittsburgh | Pennsylvania |
United States | Research Site | Plano | Texas |
United States | Research Site | Port Charlotte | Florida |
United States | Research Site | Port Huron | Michigan |
United States | Research Site | Richmond | Virginia |
United States | Research Site | Richmond | Virginia |
United States | Research Site | Rolling Hills Estates | California |
United States | Research Site | Saint Louis | Missouri |
United States | Research Site | Saint Louis | Missouri |
United States | Research Site | Saint Petersburg | Florida |
United States | Research Site | Saint Petersburg | Florida |
United States | Research Site | Saint Petersburg | Florida |
United States | Research Site | San Antonio | Texas |
United States | Research Site | Sarasota | Florida |
United States | Research Site | Savannah | Georgia |
United States | Research Site | Sebring | Florida |
United States | Research Site | Stockbridge | Georgia |
United States | Research Site | Tampa | Florida |
United States | Research Site | Toledo | Ohio |
United States | Research Site | Toms River | New Jersey |
United States | Research Site | Troy | Michigan |
United States | Research Site | Tucson | Arizona |
United States | Research Site | Tulsa | Oklahoma |
United States | Research Site | Valhalla | New York |
United States | Research Site | Walnut Creek | California |
United States | Research Site | Warwick | Rhode Island |
United States | Research Site | Westminster | California |
United States | Research Site | White Marsh | Maryland |
United States | Research Site | Winston-Salem | North Carolina |
United States | Research Site | Winter Park | Florida |
United States | Research Site | Zachary | Louisiana |
Vietnam | Research Site | Ha Noi | |
Vietnam | Research Site | Hanoi | |
Vietnam | Research Site | Hanoi | |
Vietnam | Research Site | Ho Chi Minh |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca | Amgen |
United States, Vietnam, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Israel, Japan, Korea, Republic of, Russian Federation, Saudi Arabia, South Africa, Taiwan, Ukraine, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Annual Asthma Exacerbation Rate Associated With Hospitalisations | The annualized exacerbation rate is based on exacerbations reported by the investigator that are associated with hospitalization | From randomisation to Study Week 52 | |
Other | Annual Asthma Exacerbation Rate Using Adjudicated Data | The annualized exacerbation rate is based on exacerbations as defined for the primary endpoint, but any hospitalisation and ER visits which are adjudicated to be asthma related are added, and those adjudicated to not be asthma related are removed from analyses. | From randomisation to Study Week 52 | |
Other | Annual Asthma Exacerbation Rate Associated With Emergency Room (ER) Visit or Hospitalisation Using Adjudicated Data | The annualized exacerbation rate is based on exacerbations associated with hospitalisations or ER visits, where hospitalisation and ER visits adjudicated to be asthma related are added, and those adjudicated to not be asthma related are removed from analyses. | From randomisation to Study Week 52 | |
Primary | Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma | The annual exacerbation rate is based on unadjudicated exacerbations reported by the investigator in the eCRF. The analysis is based on the primary population (Full Analysis Set) | From randomisation to Study Week 52. | |
Primary | Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma in Subjects With Baseline Eosinophils < 300 Cells/uL | The annual exacerbation rate is based on unadjudicated exacerbations reported by the investigator in the eCRF. This analysis is based on subjects with baseline eosinophils < 300 cells/uL | From randomisation to Study Week 52. | |
Secondary | Mean Change From Baseline at Week 52 in Pre-dose/Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) (L) (Key Secondary Endpoint) | Mean change from baseline in FEV1 as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration. | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline at Week 52 in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score (Key Secondary Endpoint) | Mean change from baseline in AQLQ(S)+12 as compared to placebo at Week 52. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline at Week 52 in Asthma Control Questionnaire-6(ACQ-6) (Key Secondary Endpoint) | Change from baseline in ACQ-6 as compared to placebo at Week 52. The ACQ-6 captures asthma symptoms and short-acting ß2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses. | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline at Week 52 in Asthma Symptom Diary (Key Secondary Endpoint) | Mean change from baseline at Week 52 in Asthma Symptom Diary. The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4, where 0 indicates no asthma symptoms. | From randomisation to Study Week 52 | |
Secondary | Time to First Asthma Exacerbation | Time to first occurrence of asthma exacerbation post-randomisation, presented as number of subjects with at least one asthma exacerbation as reported by the investigator in the eCRF. | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline at Week 52 in Clinic Fractional Exhaled Nitric Oxide (FeNO) (Ppb) | Mean change from baseline at Study Week 52 in FeNO (ppb) measured at site | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline in Daily Rescue Medication Use (Weekly Means) at Week 52 | Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x [number of night nebulizer times] + number of daytime inhaler puffs + 2 x [number of day nebulizer times]. Weekly means are calculated using at least 4 of 7 days of daily rescue medication use. | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline in Work Productivity Loss Due to Asthma at Week 52 | WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline in Class Productivity Loss Due to Asthma at Week 52 | WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Class productivity loss is derived by sum of percentage of missed class hours due to asthma and product of percentage of actual hours in class times degree of asthma affecting productivity while in class. Percentage of missed hours in class due to asthma is calculated by number of hours in class missed due to asthma divided by total number of hours in class missed plus number of hours actually in class. | From randomisation to Study Week 52 | |
Secondary | Activity Impairment at Week 52 | WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Activity impairment is the degree health affected regular activities (other than work or class) rated from 0 to 10, with 0 meaning no effect, divided by 10, and then expressed as a percentage. | From randomisation to Study Week 52 | |
Secondary | Pharmacokinetics of Tezepelumab | Mean serum trough PK concentrations taken pre-dose at each visit | Pre-dose samples at Baseline, Week 4, Week 12, Week 24, Week 36, Week 52, Week 64 | |
Secondary | Mean Change From Baseline at Week 52 in EQ-5D-5L VAS | Mean change from baseline at Study Week 52 in EQ-5D-5L VAS. EQ-5D-5L visual analogue scale (VAS) allows subjects to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state. | At Study Week 52 | |
Secondary | Clinicians Global Impression of Change at Week 52 | CGIC (Clinical global impression of change) is an overall evaluation of response to treatment, conducted by investigator using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse) | From randomisation to Study Week 52 | |
Secondary | Patients Global Impression of Change at Week 52 | PGIC (Patient global impression of change) is an overall evaluation of response to treatment, conducted by the patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). | From randomisation to Study Week 52 | |
Secondary | Patients Global Impression of Severity at Week 52 | PGI-S (Patient global impression of severity) is an overall evaluation of patient's perception of overall symptom severity using a 6-point rating scale, ranging from 0 = No symptoms, 1=Very mild symptoms, 2=Mild symptoms, 3=Moderate symptoms, 4=Severe symptoms, 5=Very severe symptoms | At Study Week 52 | |
Secondary | Mean Change From Baseline at Week 52 in Blood Eosinophils (Cells/uL) | Mean change from baseline at Study Week 52 in blood eosinophils (cells/uL) | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline at Week 52 in Total Serum IgE (IU/mL) | Mean change from baseline at Study Week 52 in total serum IgE (IU/mL) | From randomisation to Study Week 52 | |
Secondary | Number of Participants With Asthma Specific Healthcare Utilization Over 52 Weeks | Number of participants with asthma specific healthcare utilizations (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 52 weeks | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline in Home Based Morning Peak Expiratory Flow (PEF) at Week 52 (Weekly Means) | Mean change from baseline in home based morning PEF (L/min) at Study Week 52. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data. | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline in Home Based Evening Peak Expiratory Flow (PEF) at Week 52 (Weekly Means) | Mean change from baseline in home based evening PEF (L/min) at Study Week 52. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data. | From randomisation to Study Week 52 | |
Secondary | Mean Change From Baseline in Night Time Awakenings (Weekly Means) at Week 52 | Mean change from baseline in night time awakenings due to asthma at Study Week 52. Night-time awakenings percentage defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean. | From randomisation to Study Week 52 | |
Secondary | Immunogenecity of Tezepelumab | Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at >=2 post baseline assessments (with >=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA. | Baseline, and from time of first dose at Week 0 to end of study at Week 64. | |
Secondary | Proportion of Subjects Who Had no Asthma Exacerbations | The proportion of subjects who have no exacerbations is presented as the percentage of subjects with no exacerbations. This is defined as subjects who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation during this period. | From randomisation to Study Week 52 | |
Secondary | Annual Asthma Exacerbation Rate Resulting in Emergency Room Visit or Hospitalisation | The annualized exacerbation rate is based on exacerbations reported by the investigator that are associated with an emergency room visit, urgent care visit, or a hospitalization (where urgent care visit was captured as an emergency room visit on the eCRF) | From randomisation to Study Week 52 | |
Secondary | Proportion of Subjects With at Least One Asthma Exacerbation Associated With Emergency Room Visit or Hospitalisation | Proportion of subjects with at least one asthma exacerbation associated with emergency room visit or hospitalisation as recorded by the investigator in the CRF. This is presented as percentage of subjects with at least one asthma exacerbation associated with emergency room visit or hospitalisation. | From randomisation to Study Week 52 | |
Secondary | Proportion of Subjects Who Had no Asthma Exacerbations Associated With Emergency Room or Hospitalisation | The proportion of subjects with no exacerbations is presented as percentage of subjects who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation associated with emergency room or hospitalisation during this period. | From randomisation to Study Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|